Janux Therapeutics, Inc.
(NASDAQ: JANX)

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

16.400

-0.710 (-4.15%)
Range 16.300 - 17.220   (5.64%)
Open 17.040
Previous Close 17.110
Bid Price 13.700
Bid Volume 9
Ask Price 15.420
Ask Volume 8
Volume 2,388,204
Value -
Remark
Delayed prices. Updated at 05 Dec 2025 05:00.
Data powered by
View All Events

Loading Chart...

Please login to view stock data and analysis